These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36055978)

  • 1. A randomized, double-blind, placebo-controlled, pharmacogenetic study of ondansetron for treating alcohol use disorder.
    Seneviratne C; Gorelick DA; Lynch KG; Brown C; Romer D; Pond T; Kampman K; Kranzler HR
    Alcohol Clin Exp Res; 2022 Oct; 46(10):1900-1912. PubMed ID: 36055978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of genotype combinations that can predict the outcome of the treatment of alcohol dependence using the 5-HT(3) antagonist ondansetron.
    Johnson BA; Seneviratne C; Wang XQ; Ait-Daoud N; Li MD
    Am J Psychiatry; 2013 Sep; 170(9):1020-31. PubMed ID: 23897038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking.
    Johnson BA; Ait-Daoud N; Seneviratne C; Roache JD; Javors MA; Wang XQ; Liu L; Penberthy JK; DiClemente CC; Li MD
    Am J Psychiatry; 2011 Mar; 168(3):265-75. PubMed ID: 21247998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ondansetron reduces naturalistic drinking in nontreatment-seeking alcohol-dependent individuals with the LL 5'-HTTLPR genotype: a laboratory study.
    Kenna GA; Zywiak WH; Swift RM; McGeary JE; Clifford JS; Shoaff JR; Vuittonet C; Fricchione S; Brickley M; Beaucage K; Haass-Koffler CL; Leggio L
    Alcohol Clin Exp Res; 2014 Jun; 38(6):1567-74. PubMed ID: 24773166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial.
    Johnson BA; Roache JD; Javors MA; DiClemente CC; Cloninger CR; Prihoda TJ; Bordnick PS; Ait-Daoud N; Hensler J
    JAMA; 2000 Aug 23-30; 284(8):963-71. PubMed ID: 10944641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A within-group design of nontreatment seeking 5-HTTLPR genotyped alcohol-dependent subjects receiving ondansetron and sertraline.
    Kenna GA; Zywiak WH; McGeary JE; Leggio L; McGeary C; Wang S; Grenga A; Swift RM
    Alcohol Clin Exp Res; 2009 Feb; 33(2):315-23. PubMed ID: 19032576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose ondansetron: A candidate prospective precision medicine to treat alcohol use disorder endophenotypes.
    Johnson B; Alho H; Addolorato G; Lesch OM; Chick J; Liu L; Schuyler V
    Eur J Intern Med; 2024 Jun; ():. PubMed ID: 38876929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association, interaction, and replication analysis of genes encoding serotonin transporter and 5-HT3 receptor subunits A and B in alcohol dependence.
    Seneviratne C; Franklin J; Beckett K; Ma JZ; Ait-Daoud N; Payne TJ; Johnson BA; Li MD
    Hum Genet; 2013 Oct; 132(10):1165-76. PubMed ID: 23757001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ondansetron and sertraline may interact with 5-HTTLPR and DRD4 polymorphisms to reduce drinking in non-treatment seeking alcohol-dependent women: exploratory findings.
    Kenna GA; Zywiak WH; Swift RM; McGeary JE; Clifford JS; Shoaff JR; Fricchione S; Brickley M; Beaucage K; Haass-Koffler CL; Leggio L
    Alcohol; 2014 Sep; 48(6):515-22. PubMed ID: 25212749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association and interaction analyses of 5-HT3 receptor and serotonin transporter genes with alcohol, cocaine, and nicotine dependence using the SAGE data.
    Yang J; Li MD
    Hum Genet; 2014 Jul; 133(7):905-18. PubMed ID: 24590108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional genetic variants that increase synaptic serotonin and 5-HT3 receptor sensitivity predict alcohol and drug dependence.
    Enoch MA; Gorodetsky E; Hodgkinson C; Roy A; Goldman D
    Mol Psychiatry; 2011 Nov; 16(11):1139-46. PubMed ID: 20838391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, placebo-controlled trial of ondansetron for the treatment of cocaine use disorder with post hoc pharmacogenetic analysis.
    Blevins D; Seneviratne C; Wang XQ; Johnson BA; Ait-Daoud N
    Drug Alcohol Depend; 2021 Nov; 228():109074. PubMed ID: 34600264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining ondansetron and naltrexone reduces craving among biologically predisposed alcoholics: preliminary clinical evidence.
    Ait-Daoud N; Johnson BA; Prihoda TJ; Hargita ID
    Psychopharmacology (Berl); 2001 Feb; 154(1):23-7. PubMed ID: 11292002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abnormalities of mucosal serotonin metabolism and 5-HT
    Gunn D; Garsed K; Lam C; Singh G; Lingaya M; Wahl V; Niesler B; Henry A; Hall IP; Whorwell P; Spiller R
    Aliment Pharmacol Ther; 2019 Sep; 50(5):538-546. PubMed ID: 31342534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidence.
    Johnson BA; Ait-Daoud N; Prihoda TJ
    Alcohol Clin Exp Res; 2000 May; 24(5):737-42. PubMed ID: 10832917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of serotonin transporter mRNA as a quantitative biomarker of heavy drinking and its comparison to ethyl glucuronide/ethyl sulfate: A randomized, double-blind, crossover trial.
    Cornell J; Conchas A; Wang XQ; Fink JC; Chen H; Kane MA; Pilli N; Ait-Daoud N; Gorelick DA; Li MD; Johnson BA; Seneviratne C
    Alcohol Clin Exp Res; 2022 Oct; 46(10):1888-1899. PubMed ID: 36031718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial.
    Faris PL; Kim SW; Meller WH; Goodale RL; Oakman SA; Hofbauer RD; Marshall AM; Daughters RS; Banerjee-Stevens D; Eckert ED; Hartman BK
    Lancet; 2000 Mar; 355(9206):792-7. PubMed ID: 10711927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pilot randomized placebo-controlled clinical trial of high-dose gabapentin for alcohol use disorder.
    Mariani JJ; Pavlicova M; Basaraba C; Mamczur-Fuller A; Brooks DJ; Bisaga A; Carpenter KM; Nunes EV; Levin FR
    Alcohol Clin Exp Res; 2021 Aug; 45(8):1639-1652. PubMed ID: 34120336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial.
    Bogenschutz MP; Ross S; Bhatt S; Baron T; Forcehimes AA; Laska E; Mennenga SE; O'Donnell K; Owens LT; Podrebarac S; Rotrosen J; Tonigan JS; Worth L
    JAMA Psychiatry; 2022 Oct; 79(10):953-962. PubMed ID: 36001306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.